Biogen (BIIB) Depreciation & Amortization (CF) (2009 - 2026)

Biogen has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $236.1 million in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 21.51% year-over-year to $236.1 million in Q2 2026; TTM through Jun 2026 was $842.9 million, a 13.25% increase from a year earlier, with the FY2025 full-year figure at $779.9 million, up 15.85% from the prior year.
• Depreciation & Amortization (CF) was $236.1 million for Q2 2026 at Biogen, up from $204.4 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $236.1 million in Q2 2026, with the low at $112.3 million in Q1 2023.
• Average Depreciation & Amortization (CF) over 5 years is $161.5 million, with a median of $153.2 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) retreated 21.52% in 2023, then jumped 46.24% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $119.8 million in 2022, then gained by 16.94% to $140.1 million in 2023, then jumped by 31.33% to $184.0 million in 2024, then rose by 8.8% to $200.2 million in 2025, then grew by 17.93% to $236.1 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $236.1 million (Q2 2026), $204.4 million (Q1 2026), and $200.2 million (Q4 2025), per Business Quant data.